Plenvu

Chronic Pain, Catarrh, Acute Bronchitis + 8 more
Treatment
3 FDA approvals
20 Active Studies for Plenvu

What is Plenvu

Sodium ascorbateThe Generic name of this drug
Hemocyte Plusis the brand name
image of different drug pills on a surface
Plenvu Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Hemocyte Plus
Sodium ascorbate
2002
6

Approved as Treatment by the FDA

Sodium ascorbate, also known as Hemocyte Plus, is approved by the FDA for 3 uses including Nutritional supplementation and Vitamin supplementation .
Nutritional supplementation
Vitamin supplementation
Used in combination with Sodium ascorbate for Vitamin supplementation
Vitamin supplementation therapy
Used in combination with Sodium ascorbate for Vitamin supplementation therapy

When to interrupt dosage

The amount of Plenvu is contingent upon the established disorder, including Throat irritation, Catarrh and Influenza. The dosage may vary as per the procedure of administration (e.g. Oral or Capsule - Oral) specified in the table underneath.
Condition
Dosage
Administration
Vitamin supplementation therapy
60.0 mg, , 250.0 mg, 500.0 mg, 50.0 mg, 4700.0 mg, 20.0 mg, 10.0 mg, 100.0 mg, 85.0 mg, 200.0 mg, 5.9 mg/mL, 36.0 mg, 500.0 mg/mL, 120.0 mg, 48110.0 mg, 5900.0 mg, 393.0 mg, 37.5 mg, 394.7 mg, 67.5 mg, 197.0 mg, 337.5 mg, 84.5 mg, 56.0 mg, 45.0 mg, 140.0 mg, 280.0 mg, 343.0 mg, 855.0 mg, 112.5 mg, 575.0 mg, 79.0 mg, 171.0 mg, 159.0 mg, 300.0 mg, 121.4 mg, 227.0 mg, 143.3 mg, 242.72 mg, 78.8 mg, 483.0 mg, 169.0 mg, 277.5 mg, 114.0 mg, 242.7 mg, 59.0 mg, 56.24 mg, 57.0 mg, 566.0 mg, 121.36 mg, 338.0 mg, 72.0 mg, 187.0 mg, 300.0 mg/mL, 250.0 mg/mL, 0.8888 mg/mg, 0.01 mg/mg, 50.0 mg/mL, 35.0 mg/mL
, Tablet, Tablet - Oral, Oral, Liquid - Intramuscular; Intravenous, Liquid, Intramuscular; Intravenous, Powder, Powder - Oral, Wafer, Wafer - Oral, Intravenous, Solution - Intravenous, Solution, Powder, for solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Capsule, Kit, Tablet, chewable, Tablet, chewable - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Powder, for solution, Lozenge, Lozenge - Oral, Liquid - Oral, Kit - Oral, Solution - Oral
Catarrh
60.0 mg, , 250.0 mg, 500.0 mg, 50.0 mg, 4700.0 mg, 20.0 mg, 10.0 mg, 100.0 mg, 85.0 mg, 200.0 mg, 5.9 mg/mL, 36.0 mg, 500.0 mg/mL, 120.0 mg, 48110.0 mg, 5900.0 mg, 393.0 mg, 37.5 mg, 394.7 mg, 67.5 mg, 197.0 mg, 337.5 mg, 84.5 mg, 56.0 mg, 45.0 mg, 140.0 mg, 280.0 mg, 343.0 mg, 855.0 mg, 112.5 mg, 575.0 mg, 79.0 mg, 171.0 mg, 159.0 mg, 300.0 mg, 121.4 mg, 227.0 mg, 143.3 mg, 242.72 mg, 78.8 mg, 483.0 mg, 169.0 mg, 277.5 mg, 114.0 mg, 242.7 mg, 59.0 mg, 56.24 mg, 57.0 mg, 566.0 mg, 121.36 mg, 338.0 mg, 72.0 mg, 187.0 mg, 300.0 mg/mL, 250.0 mg/mL, 0.8888 mg/mg, 0.01 mg/mg, 50.0 mg/mL, 35.0 mg/mL
, Tablet, Tablet - Oral, Oral, Liquid - Intramuscular; Intravenous, Liquid, Intramuscular; Intravenous, Powder, Powder - Oral, Wafer, Wafer - Oral, Intravenous, Solution - Intravenous, Solution, Powder, for solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Capsule, Kit, Tablet, chewable, Tablet, chewable - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Powder, for solution, Lozenge, Lozenge - Oral, Liquid - Oral, Kit - Oral, Solution - Oral
Fever
60.0 mg, , 250.0 mg, 500.0 mg, 50.0 mg, 4700.0 mg, 20.0 mg, 10.0 mg, 100.0 mg, 85.0 mg, 200.0 mg, 5.9 mg/mL, 36.0 mg, 500.0 mg/mL, 120.0 mg, 48110.0 mg, 5900.0 mg, 393.0 mg, 37.5 mg, 394.7 mg, 67.5 mg, 197.0 mg, 337.5 mg, 84.5 mg, 56.0 mg, 45.0 mg, 140.0 mg, 280.0 mg, 343.0 mg, 855.0 mg, 112.5 mg, 575.0 mg, 79.0 mg, 171.0 mg, 159.0 mg, 300.0 mg, 121.4 mg, 227.0 mg, 143.3 mg, 242.72 mg, 78.8 mg, 483.0 mg, 169.0 mg, 277.5 mg, 114.0 mg, 242.7 mg, 59.0 mg, 56.24 mg, 57.0 mg, 566.0 mg, 121.36 mg, 338.0 mg, 72.0 mg, 187.0 mg, 300.0 mg/mL, 250.0 mg/mL, 0.8888 mg/mg, 0.01 mg/mg, 50.0 mg/mL, 35.0 mg/mL
, Tablet, Tablet - Oral, Oral, Liquid - Intramuscular; Intravenous, Liquid, Intramuscular; Intravenous, Powder, Powder - Oral, Wafer, Wafer - Oral, Intravenous, Solution - Intravenous, Solution, Powder, for solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Capsule, Kit, Tablet, chewable, Tablet, chewable - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Powder, for solution, Lozenge, Lozenge - Oral, Liquid - Oral, Kit - Oral, Solution - Oral
Acute Bronchitis
60.0 mg, , 250.0 mg, 500.0 mg, 50.0 mg, 4700.0 mg, 20.0 mg, 10.0 mg, 100.0 mg, 85.0 mg, 200.0 mg, 5.9 mg/mL, 36.0 mg, 500.0 mg/mL, 120.0 mg, 48110.0 mg, 5900.0 mg, 393.0 mg, 37.5 mg, 394.7 mg, 67.5 mg, 197.0 mg, 337.5 mg, 84.5 mg, 56.0 mg, 45.0 mg, 140.0 mg, 280.0 mg, 343.0 mg, 855.0 mg, 112.5 mg, 575.0 mg, 79.0 mg, 171.0 mg, 159.0 mg, 300.0 mg, 121.4 mg, 227.0 mg, 143.3 mg, 242.72 mg, 78.8 mg, 483.0 mg, 169.0 mg, 277.5 mg, 114.0 mg, 242.7 mg, 59.0 mg, 56.24 mg, 57.0 mg, 566.0 mg, 121.36 mg, 338.0 mg, 72.0 mg, 187.0 mg, 300.0 mg/mL, 250.0 mg/mL, 0.8888 mg/mg, 0.01 mg/mg, 50.0 mg/mL, 35.0 mg/mL
, Tablet, Tablet - Oral, Oral, Liquid - Intramuscular; Intravenous, Liquid, Intramuscular; Intravenous, Powder, Powder - Oral, Wafer, Wafer - Oral, Intravenous, Solution - Intravenous, Solution, Powder, for solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Capsule, Kit, Tablet, chewable, Tablet, chewable - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Powder, for solution, Lozenge, Lozenge - Oral, Liquid - Oral, Kit - Oral, Solution - Oral
Throat irritation
60.0 mg, , 250.0 mg, 500.0 mg, 50.0 mg, 4700.0 mg, 20.0 mg, 10.0 mg, 100.0 mg, 85.0 mg, 200.0 mg, 5.9 mg/mL, 36.0 mg, 500.0 mg/mL, 120.0 mg, 48110.0 mg, 5900.0 mg, 393.0 mg, 37.5 mg, 394.7 mg, 67.5 mg, 197.0 mg, 337.5 mg, 84.5 mg, 56.0 mg, 45.0 mg, 140.0 mg, 280.0 mg, 343.0 mg, 855.0 mg, 112.5 mg, 575.0 mg, 79.0 mg, 171.0 mg, 159.0 mg, 300.0 mg, 121.4 mg, 227.0 mg, 143.3 mg, 242.72 mg, 78.8 mg, 483.0 mg, 169.0 mg, 277.5 mg, 114.0 mg, 242.7 mg, 59.0 mg, 56.24 mg, 57.0 mg, 566.0 mg, 121.36 mg, 338.0 mg, 72.0 mg, 187.0 mg, 300.0 mg/mL, 250.0 mg/mL, 0.8888 mg/mg, 0.01 mg/mg, 50.0 mg/mL, 35.0 mg/mL
, Tablet, Tablet - Oral, Oral, Liquid - Intramuscular; Intravenous, Liquid, Intramuscular; Intravenous, Powder, Powder - Oral, Wafer, Wafer - Oral, Intravenous, Solution - Intravenous, Solution, Powder, for solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Capsule, Kit, Tablet, chewable, Tablet, chewable - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Powder, for solution, Lozenge, Lozenge - Oral, Liquid - Oral, Kit - Oral, Solution - Oral
Influenza
60.0 mg, , 250.0 mg, 500.0 mg, 50.0 mg, 4700.0 mg, 20.0 mg, 10.0 mg, 100.0 mg, 85.0 mg, 200.0 mg, 5.9 mg/mL, 36.0 mg, 500.0 mg/mL, 120.0 mg, 48110.0 mg, 5900.0 mg, 393.0 mg, 37.5 mg, 394.7 mg, 67.5 mg, 197.0 mg, 337.5 mg, 84.5 mg, 56.0 mg, 45.0 mg, 140.0 mg, 280.0 mg, 343.0 mg, 855.0 mg, 112.5 mg, 575.0 mg, 79.0 mg, 171.0 mg, 159.0 mg, 300.0 mg, 121.4 mg, 227.0 mg, 143.3 mg, 242.72 mg, 78.8 mg, 483.0 mg, 169.0 mg, 277.5 mg, 114.0 mg, 242.7 mg, 59.0 mg, 56.24 mg, 57.0 mg, 566.0 mg, 121.36 mg, 338.0 mg, 72.0 mg, 187.0 mg, 300.0 mg/mL, 250.0 mg/mL, 0.8888 mg/mg, 0.01 mg/mg, 50.0 mg/mL, 35.0 mg/mL
, Tablet, Tablet - Oral, Oral, Liquid - Intramuscular; Intravenous, Liquid, Intramuscular; Intravenous, Powder, Powder - Oral, Wafer, Wafer - Oral, Intravenous, Solution - Intravenous, Solution, Powder, for solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Capsule, Kit, Tablet, chewable, Tablet, chewable - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Powder, for solution, Lozenge, Lozenge - Oral, Liquid - Oral, Kit - Oral, Solution - Oral
Vitamin supplementation
60.0 mg, , 250.0 mg, 500.0 mg, 50.0 mg, 4700.0 mg, 20.0 mg, 10.0 mg, 100.0 mg, 85.0 mg, 200.0 mg, 5.9 mg/mL, 36.0 mg, 500.0 mg/mL, 120.0 mg, 48110.0 mg, 5900.0 mg, 393.0 mg, 37.5 mg, 394.7 mg, 67.5 mg, 197.0 mg, 337.5 mg, 84.5 mg, 56.0 mg, 45.0 mg, 140.0 mg, 280.0 mg, 343.0 mg, 855.0 mg, 112.5 mg, 575.0 mg, 79.0 mg, 171.0 mg, 159.0 mg, 300.0 mg, 121.4 mg, 227.0 mg, 143.3 mg, 242.72 mg, 78.8 mg, 483.0 mg, 169.0 mg, 277.5 mg, 114.0 mg, 242.7 mg, 59.0 mg, 56.24 mg, 57.0 mg, 566.0 mg, 121.36 mg, 338.0 mg, 72.0 mg, 187.0 mg, 300.0 mg/mL, 250.0 mg/mL, 0.8888 mg/mg, 0.01 mg/mg, 50.0 mg/mL, 35.0 mg/mL
, Tablet, Tablet - Oral, Oral, Liquid - Intramuscular; Intravenous, Liquid, Intramuscular; Intravenous, Powder, Powder - Oral, Wafer, Wafer - Oral, Intravenous, Solution - Intravenous, Solution, Powder, for solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Capsule, Kit, Tablet, chewable, Tablet, chewable - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Powder, for solution, Lozenge, Lozenge - Oral, Liquid - Oral, Kit - Oral, Solution - Oral
Nutritional supplementation
60.0 mg, , 250.0 mg, 500.0 mg, 50.0 mg, 4700.0 mg, 20.0 mg, 10.0 mg, 100.0 mg, 85.0 mg, 200.0 mg, 5.9 mg/mL, 36.0 mg, 500.0 mg/mL, 120.0 mg, 48110.0 mg, 5900.0 mg, 393.0 mg, 37.5 mg, 394.7 mg, 67.5 mg, 197.0 mg, 337.5 mg, 84.5 mg, 56.0 mg, 45.0 mg, 140.0 mg, 280.0 mg, 343.0 mg, 855.0 mg, 112.5 mg, 575.0 mg, 79.0 mg, 171.0 mg, 159.0 mg, 300.0 mg, 121.4 mg, 227.0 mg, 143.3 mg, 242.72 mg, 78.8 mg, 483.0 mg, 169.0 mg, 277.5 mg, 114.0 mg, 242.7 mg, 59.0 mg, 56.24 mg, 57.0 mg, 566.0 mg, 121.36 mg, 338.0 mg, 72.0 mg, 187.0 mg, 300.0 mg/mL, 250.0 mg/mL, 0.8888 mg/mg, 0.01 mg/mg, 50.0 mg/mL, 35.0 mg/mL
, Tablet, Tablet - Oral, Oral, Liquid - Intramuscular; Intravenous, Liquid, Intramuscular; Intravenous, Powder, Powder - Oral, Wafer, Wafer - Oral, Intravenous, Solution - Intravenous, Solution, Powder, for solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Capsule, Kit, Tablet, chewable, Tablet, chewable - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Powder, for solution, Lozenge, Lozenge - Oral, Liquid - Oral, Kit - Oral, Solution - Oral
Hoarseness
60.0 mg, , 250.0 mg, 500.0 mg, 50.0 mg, 4700.0 mg, 20.0 mg, 10.0 mg, 100.0 mg, 85.0 mg, 200.0 mg, 5.9 mg/mL, 36.0 mg, 500.0 mg/mL, 120.0 mg, 48110.0 mg, 5900.0 mg, 393.0 mg, 37.5 mg, 394.7 mg, 67.5 mg, 197.0 mg, 337.5 mg, 84.5 mg, 56.0 mg, 45.0 mg, 140.0 mg, 280.0 mg, 343.0 mg, 855.0 mg, 112.5 mg, 575.0 mg, 79.0 mg, 171.0 mg, 159.0 mg, 300.0 mg, 121.4 mg, 227.0 mg, 143.3 mg, 242.72 mg, 78.8 mg, 483.0 mg, 169.0 mg, 277.5 mg, 114.0 mg, 242.7 mg, 59.0 mg, 56.24 mg, 57.0 mg, 566.0 mg, 121.36 mg, 338.0 mg, 72.0 mg, 187.0 mg, 300.0 mg/mL, 250.0 mg/mL, 0.8888 mg/mg, 0.01 mg/mg, 50.0 mg/mL, 35.0 mg/mL
, Tablet, Tablet - Oral, Oral, Liquid - Intramuscular; Intravenous, Liquid, Intramuscular; Intravenous, Powder, Powder - Oral, Wafer, Wafer - Oral, Intravenous, Solution - Intravenous, Solution, Powder, for solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Capsule, Kit, Tablet, chewable, Tablet, chewable - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Powder, for solution, Lozenge, Lozenge - Oral, Liquid - Oral, Kit - Oral, Solution - Oral
Airway secretion clearance therapy
60.0 mg, , 250.0 mg, 500.0 mg, 50.0 mg, 4700.0 mg, 20.0 mg, 10.0 mg, 100.0 mg, 85.0 mg, 200.0 mg, 5.9 mg/mL, 36.0 mg, 500.0 mg/mL, 120.0 mg, 48110.0 mg, 5900.0 mg, 393.0 mg, 37.5 mg, 394.7 mg, 67.5 mg, 197.0 mg, 337.5 mg, 84.5 mg, 56.0 mg, 45.0 mg, 140.0 mg, 280.0 mg, 343.0 mg, 855.0 mg, 112.5 mg, 575.0 mg, 79.0 mg, 171.0 mg, 159.0 mg, 300.0 mg, 121.4 mg, 227.0 mg, 143.3 mg, 242.72 mg, 78.8 mg, 483.0 mg, 169.0 mg, 277.5 mg, 114.0 mg, 242.7 mg, 59.0 mg, 56.24 mg, 57.0 mg, 566.0 mg, 121.36 mg, 338.0 mg, 72.0 mg, 187.0 mg, 300.0 mg/mL, 250.0 mg/mL, 0.8888 mg/mg, 0.01 mg/mg, 50.0 mg/mL, 35.0 mg/mL
, Tablet, Tablet - Oral, Oral, Liquid - Intramuscular; Intravenous, Liquid, Intramuscular; Intravenous, Powder, Powder - Oral, Wafer, Wafer - Oral, Intravenous, Solution - Intravenous, Solution, Powder, for solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Capsule, Kit, Tablet, chewable, Tablet, chewable - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Powder, for solution, Lozenge, Lozenge - Oral, Liquid - Oral, Kit - Oral, Solution - Oral
Chronic Pain
60.0 mg, , 250.0 mg, 500.0 mg, 50.0 mg, 4700.0 mg, 20.0 mg, 10.0 mg, 100.0 mg, 85.0 mg, 200.0 mg, 5.9 mg/mL, 36.0 mg, 500.0 mg/mL, 120.0 mg, 48110.0 mg, 5900.0 mg, 393.0 mg, 37.5 mg, 394.7 mg, 67.5 mg, 197.0 mg, 337.5 mg, 84.5 mg, 56.0 mg, 45.0 mg, 140.0 mg, 280.0 mg, 343.0 mg, 855.0 mg, 112.5 mg, 575.0 mg, 79.0 mg, 171.0 mg, 159.0 mg, 300.0 mg, 121.4 mg, 227.0 mg, 143.3 mg, 242.72 mg, 78.8 mg, 483.0 mg, 169.0 mg, 277.5 mg, 114.0 mg, 242.7 mg, 59.0 mg, 56.24 mg, 57.0 mg, 566.0 mg, 121.36 mg, 338.0 mg, 72.0 mg, 187.0 mg, 300.0 mg/mL, 250.0 mg/mL, 0.8888 mg/mg, 0.01 mg/mg, 50.0 mg/mL, 35.0 mg/mL
, Tablet, Tablet - Oral, Oral, Liquid - Intramuscular; Intravenous, Liquid, Intramuscular; Intravenous, Powder, Powder - Oral, Wafer, Wafer - Oral, Intravenous, Solution - Intravenous, Solution, Powder, for solution - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule - Oral, Capsule, Kit, Tablet, chewable, Tablet, chewable - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated, Powder, for solution, Lozenge, Lozenge - Oral, Liquid - Oral, Kit - Oral, Solution - Oral

Warnings

There are 20 known major drug interactions with Plenvu.
Common Plenvu Drug Interactions
Drug Name
Risk Level
Description
Alloin
Minor
The risk or severity of adverse effects can be increased when Sodium ascorbate is combined with Alloin.
Calcium polycarbophil
Minor
The risk or severity of adverse effects can be increased when Sodium ascorbate is combined with Calcium polycarbophil.
Chlorpropamide
Minor
Sodium ascorbate may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Frangula purshiana bark
Minor
The risk or severity of adverse effects can be increased when Sodium ascorbate is combined with Frangula purshiana bark.
Konjac mannan
Minor
The risk or severity of adverse effects can be increased when Sodium ascorbate is combined with Konjac mannan.
image of a doctor in a lab doing drug, clinical research

Plenvu Novel Uses: Which Conditions Have a Clinical Trial Featuring Plenvu?

249 active studies are presently evaluating the potential of Plenvu to provide Vitamin supplementation therapy, Chronic Pain relief and Hoarseness relief for certain conditions.
Condition
Clinical Trials
Trial Phases
Chronic Pain
130 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 3, Early Phase 1, Phase 1
Vitamin supplementation
0 Actively Recruiting
Acute Bronchitis
7 Actively Recruiting
Phase 4, Not Applicable, Phase 3, Early Phase 1
Airway secretion clearance therapy
0 Actively Recruiting
Fever
2 Actively Recruiting
Not Applicable, Phase 4
Nutritional supplementation
0 Actively Recruiting
Hoarseness
0 Actively Recruiting
Catarrh
0 Actively Recruiting
Influenza
29 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3
Throat irritation
0 Actively Recruiting
Vitamin supplementation therapy
0 Actively Recruiting

Plenvu Reviews: What are patients saying about Plenvu?

5Patient Review
9/22/2022
Plenvu for Emptying of the Bowel
Plenvu is by far the best bowel cleanse product I have tried. You only have to drink the solution two times and it doesn't leave you feeling dried out like other products do. The taste is also not bad at all - if you've ever had oral MRI imaging solution, this is much easier to stomach. I would highly recommend it to anyone who needs a good cleansing product.
5Patient Review
10/21/2022
Plenvu for Emptying of the Bowel
I mixed the two doses with clear Gatorlyte, cherry lime flavor. The taste was not bad. I'm 45 years old and it went well for me.
4.3Patient Review
11/9/2022
Plenvu for Emptying of the Bowel
I was very anxious about this prep, but it honestly wasn't as bad as I thought it would be. I sipped on the prep and then immediately drank water after. Just paced myself and used a straw so I wouldn't gulp it down too fast.
4Patient Review
9/25/2022
Plenvu for Emptying of the Bowel
I was really pleased with how this bowel prep went. I followed the instructions to a T and everything happened as it should have. The second dose was tough, but that's to be expected. Overall, I would definitely recommend this product.
3.7Patient Review
10/7/2022
Plenvu for Emptying of the Bowel
The taste is better than most preps, but it's still not great. I followed the low residual diet as prescribed, but there was still fecal matter in my bowels. The prep wasn't good enough.
3Patient Review
9/21/2022
Plenvu for Emptying of the Bowel
This medication works but is very harsh. The taste is incredibly unpleasant, and it made me want to vomit. I'll be looking for something else next time.
2.7Patient Review
10/17/2022
Plenvu for Emptying of the Bowel
I was violently ill after taking the second dose of this medication.
2Patient Review
11/2/2022
Plenvu for Emptying of the Bowel
The first dose was gross tasting but I managed to keep it down. The second dose, however, led to me vomiting it up immediately. I'm not sure if it was successful or not, but if not then this entire process has been a waste of time. I much prefer the old-school one shot method to this stuff.
1.7Patient Review
10/26/2022
Plenvu for Emptying of the Bowel
Vomited after the second dose. Didn't clean me out at all, unfortunately. This was my fifth colonoscopy and I'll have to go through it again because of this product's ineffectiveness.
1Patient Review
9/23/2022
Plenvu for Emptying of the Bowel
This was an absolutely terrible experience. The taste is unbearable, and I ended up regurgitating after only drinking half the second dose. Do not recommend this to anyone.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about plenvu

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Plenvu a good colonoscopy prep?

"The average rating for Plenvu as a treatment for Bowel Preparation is 4.7 out of 10 from a total of 317 ratings."

Answered by AI

What is Plenvu medication?

"PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride for oral solution) is a prescription medication that adults take to clean the colon before a colonoscopy."

Answered by AI

How fast should you drink Plenvu?

"slowly drink the mixture over the course of 30 minutes."

Answered by AI

Do you have to drink Plenvu slowly?

"Make sure to drink all bowel preparation doses slowly, using small sips over at least 30 minutes. You can also take a break from drinking the preparation if needed, but continue once the nausea and/or vomiting has subsided."

Answered by AI

Clinical Trials for Plenvu

Have you considered Plenvu clinical trials? We made a collection of clinical trials featuring Plenvu, we think they might fit your search criteria.Go to Trials
Image of Baylor College of Medicine/Texas Children's Hospital in Austin, United States.

Guided Imagery Therapy for Abdominal Pain

7 - 12
All Sexes
Austin, TX
Chronic abdominal pain is common among children, and the majority of cases are attributed to functional abdominal pain disorders. One approach to treating these disorders is by using psychological therapies. This clinical trial aims to see how well pre-recorded guided imagery therapy sessions help children's abdominal pain when delivered via a mobile application (app) on a smartphone or tablet. Participants will complete a baseline abdominal pain and stooling diary to determine eligibility, as well as other surveys. Eligible participants will be given access to the guided imagery therapy mobile application. This intervention asks participants to listen to a 10- to 15-minute GIT session 5 out of 7 days per week for 8 weeks, in addition to their usual care for their abdominal pain. Then, participants will complete another abdominal pain and stooling diary, along with other psychometric surveys, at the end of this intervention period. Participants will also collect another diary and surveys 3 months post-treatment.
Waitlist Available
Has No Placebo
Baylor College of Medicine/Texas Children's Hospital (+1 Sites)
Image of National Institutes of Health Clinical Center in Bethesda, United States.

BPL-1357 for Flu

18 - 55
All Sexes
Bethesda, MD
Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: To test an experimental flu vaccine. Eligibility: Healthy people aged 18 to 55 years. Design: The study will last 5 to 8 months and has 2 phases, A and B. The study vaccine will be given either as a shot in the arm or as a nasal spray. Participants will receive 1 of 3 combinations: (1) study vaccine in the nose and placebo in the arm; (2) placebo in the nose and study vaccine in the arm; or (3) placebo in the nose and placebo in the arm. A placebo is just like the real vaccine but contains no active ingredients. Phase A: Participants will have 5 clinic visits over 56 days. They will receive a shot and a nasal spray at 2 of the visits, 28 days apart. At each visit, they will have a physical exam, with tests of their blood, urine, and nasal secretions. They will check their temperature at home and record any symptoms for 7 days after each vaccine. Phase B: Participants will stay in the hospital for at least 9 days. They will be infected with a flu virus. They will provide blood, urine, and nasal fluid samples. They will have tests of their heart function. They will remain in the hospital until they test negative for the flu 2 days in a row. They will have 2 follow-up visits, 4 and 8 weeks after leaving the hospital.
Phase 2
Waitlist Available
National Institutes of Health Clinical Center (+1 Sites)Luca T Giurgea, M.D.
Image of Vanderbilt University Medical Center in Nashville, United States.

High vs. Standard Dose Influenza Vaccines for Flu

18+
All Sexes
Nashville, TN
This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza: * Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season? * What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season? * What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant? * Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?
Phase 2
Recruiting
Vanderbilt University Medical CenterNatahsa Halasa, MD, MPH
Have you considered Plenvu clinical trials? We made a collection of clinical trials featuring Plenvu, we think they might fit your search criteria.Go to Trials
Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Erector Spinae Plane Block for Pain

21 - 75
All Sexes
Cleveland, OH
As per usual care for spine surgery, participants will have their back cleaned with alcohol and a needle will be placed using ultrasound for the ESP block. Through the needle, a small catheter will be placed in the participants back and the needle removed. Approximately one hour prior to the start of surgery, a numbing medication (ropivacaine, similar to Novocaine) in combination with dexmedetomidine (a pain medicine that is used in nerve block and that is not a narcotic) and contrast dye (iohexol) will be injected through the catheter. Participants will then go through the QST procedure (test of buzzing sensation and temperature sensation through pads applied to their skin) to assess the numb areas and then head to the operating room. In the operating room, the catheter will be removed after the surgeon obtains baseline CT scan images of the spine. Once surgery is completed, investigators will record pain scores over the next four days in the hospital and the amount of pain medication needed for controlling pain related to the surgery.
Recruiting
Has No Placebo
University Hospitals Cleveland Medical CenterSalim Hayek, MD
Image of Altasciences Inc - Kansas City in Overland Park, United States.

VNT-101 for Safety and Tolerability Study

18 - 59
All Sexes
Overland Park, KS
A randomized, double-blind, placebo-controlled Phase 1 study conducted at a single center with approximately 78 healthy adults aged 18-59 years. Part 1 Single Ascending Dose (SAD) will enroll 48 participants into six cohorts (S1-S6) to receive single oral doses of VNT-101 (100-1500 mg) or placebo under fasting or fed (S5 only) conditions. Part 2 Multiple Ascending Dose (MAD) will enroll 30 participants into three cohorts (M1-M3) to receive multiple oral doses of VNT-101 (250-750 mg BID Days 1-5, QD Day 6) or placebo under fasting conditions. Dose escalation in both parts will proceed after Protocol Safety Review Team (PSRT) review. The primary objective for Part 1 is to evaluate the safety and tolerability of single ascending oral (SAD) doses of VNT-101 in healthy adult participants under either fasting or fed conditions. The primary objective for part 2 is to evaluate the safety and tolerability of multiple ascending oral (MAD) doses of VNT-101 in healthy adult participants.
Phase 1
Recruiting
Altasciences Inc - Kansas City
Have you considered Plenvu clinical trials? We made a collection of clinical trials featuring Plenvu, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security